JP5932647B2 - エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用 - Google Patents

エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用 Download PDF

Info

Publication number
JP5932647B2
JP5932647B2 JP2012530319A JP2012530319A JP5932647B2 JP 5932647 B2 JP5932647 B2 JP 5932647B2 JP 2012530319 A JP2012530319 A JP 2012530319A JP 2012530319 A JP2012530319 A JP 2012530319A JP 5932647 B2 JP5932647 B2 JP 5932647B2
Authority
JP
Japan
Prior art keywords
polypeptide
chimeric polypeptide
peptide
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012530319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505713A (ja
JP2013505713A5 (enExample
Inventor
ゼーヌ エル アビディーヌ マムン ロベール
ゼーヌ エル アビディーヌ マムン ロベール
Original Assignee
サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス）
サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス）
ユニベルシテ モンペリエ ２ スイヤーンス エ テクニーク
ユニベルシテ モンペリエ ２ スイヤーンス エ テクニーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス）, サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス）, ユニベルシテ モンペリエ ２ スイヤーンス エ テクニーク, ユニベルシテ モンペリエ ２ スイヤーンス エ テクニーク filed Critical サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス）
Publication of JP2013505713A publication Critical patent/JP2013505713A/ja
Publication of JP2013505713A5 publication Critical patent/JP2013505713A5/ja
Application granted granted Critical
Publication of JP5932647B2 publication Critical patent/JP5932647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012530319A 2009-09-24 2010-09-23 エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用 Active JP5932647B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0904576A FR2950350B1 (fr) 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
FR09/04576 2009-09-24
PCT/FR2010/052006 WO2011036416A1 (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Publications (3)

Publication Number Publication Date
JP2013505713A JP2013505713A (ja) 2013-02-21
JP2013505713A5 JP2013505713A5 (enExample) 2013-04-25
JP5932647B2 true JP5932647B2 (ja) 2016-06-08

Family

ID=42107419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012530319A Active JP5932647B2 (ja) 2009-09-24 2010-09-23 エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用

Country Status (6)

Country Link
US (1) US9611481B2 (enExample)
EP (1) EP2480672B8 (enExample)
JP (1) JP5932647B2 (enExample)
CA (1) CA2775151C (enExample)
FR (1) FR2950350B1 (enExample)
WO (1) WO2011036416A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904382A1 (en) * 2013-03-15 2014-09-25 Novavax, Inc. Enhanced expression of picornavirus proteins
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
PL228341B1 (pl) * 2014-04-21 2018-03-30 Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
CA3002520A1 (en) * 2016-09-30 2018-04-05 Cellex Life Sciences, Incorporated Compositions containing protein loaded exosome and methods for preparing and delivering the same
MX2021005636A (es) 2018-11-16 2021-07-06 Codiak Biosciences Inc Vesículas extracelulares modificadas y sus usos.
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
CN113747925B (zh) 2019-03-21 2024-10-15 隆萨销售股份公司 胞外囊泡缀合物及其用途
CN114008069A (zh) 2019-04-17 2022-02-01 科迪亚克生物科学公司 外来体和aav的组合物
EP3973969A4 (en) * 2019-09-02 2023-07-12 Kyungpook National University Industry-Academic Cooperation Foundation COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER, CONTAINING, AS ACTIVE PRINCIPLE, EXTRACELLULAR VESICLES EXPRESSING IL-2 ON THE SURFACE
WO2021144363A1 (en) 2020-01-14 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic reactivity of a peptide mimicking the glycan loop of flaviviruses envelope protein
JP7562682B2 (ja) * 2020-01-27 2024-10-07 マントラ バイオ，インコーポレイテッド キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用
WO2021159016A1 (en) 2020-02-05 2021-08-12 Diadem Biotherapeutics Inc. Artificial synapses
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021216615A1 (en) * 2020-04-20 2021-10-28 The General Hospital Corporation Highly-networked coronavirus immunogen composition
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US20230295229A1 (en) * 2020-08-11 2023-09-21 Kyungpook National University Industry-Academic Cooperation Foundation Peptide selectively binding to cancer cell-derived exosome, and uses thereof
EP3973985A1 (en) * 2020-09-29 2022-03-30 Ciloa Extracellular vesicles harboring a spike protein, nucleic acids for producing the same, and method of immunizing a subject against sars-cov-2 using the same
CN113480666B (zh) * 2021-08-13 2024-01-26 郑州伊美诺生物技术有限公司 Ca153融合蛋白及其制备方法和ca153检测质控品或校准品
EP4525923A1 (en) 2022-05-20 2025-03-26 Ciloa Reversible loading of proteins in the lumen of extracellular vesicles
EP4612190A2 (en) * 2022-11-02 2025-09-10 Pioneer Biolabs, LLC Systems and methods for single cell detection of protein secretion
WO2024251819A1 (en) * 2023-06-05 2024-12-12 Ciloa Chimeric polypeptides, extracellular vesicles comprising the same, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160142A0 (en) 2001-08-17 2004-06-20 Anosys Inc Methods and compounds for the targeting of protein to exosomes
CN1639323A (zh) 2002-03-14 2005-07-13 阿诺塞斯公司 T细胞来源囊泡的功能化及其在制备免疫原性药用组合物中的应用
JP4939926B2 (ja) 2003-02-14 2012-05-30 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes

Also Published As

Publication number Publication date
EP2480672B8 (fr) 2017-03-22
EP2480672B1 (fr) 2016-12-28
CA2775151C (fr) 2019-01-22
EP2480672A1 (fr) 2012-08-01
CA2775151A1 (fr) 2011-03-31
FR2950350B1 (fr) 2013-12-13
JP2013505713A (ja) 2013-02-21
WO2011036416A1 (fr) 2011-03-31
FR2950350A1 (fr) 2011-03-25
US9611481B2 (en) 2017-04-04
US20120321653A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
JP5932647B2 (ja) エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用
JP5727361B2 (ja) エキソソームに結合して目的のポリペプチドの分泌を可能にするキメラポリヌクレオチド及びポリペプチド、並びに免疫原性組成物の産生におけるこれらの使用
CN115551545A (zh) SARS-COV-2 mRNA结构域疫苗
CN103747797A (zh) 脂质体制剂
CN101321781A (zh) 一种核苷酸疫苗
US20240294580A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
JP2010540674A (ja) Ｈｉｖ特異抗体に基づくｈｉｖ予防ワクチン
CN112552413B (zh) 新型冠状病毒重组蛋白亚单位疫苗
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
CN117279659A (zh) 人偏肺病毒疫苗
CA3207878A1 (en) Coronavirus spike protein designs, compositions and methods for their use
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
CN111148528A (zh) 流感疫苗
US20240307524A1 (en) Coronavirus vaccines
WO2024112359A1 (en) Genetic enhancement of exosome production
KR20230112691A (ko) 바이러스 감염을 치료하기 위한 방법 및 조성물
US20240092840A1 (en) Vaccine formulation comprising recombinant overlapping peptides and native proteins
CA3254064A1 (en) Immunogenic compositions against SARS-CoV-2
WO2024073005A2 (en) Exosome display compositions
WO2025076013A1 (en) Engineered middle east respiratory syndrome proteins and related methods
WO2025024336A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
WO2022165085A1 (en) Kits and methods for nucleic acid delivery
WO2025106754A1 (en) Coronavirus vaccine
CN106337038A (zh) 一种通过转肽酶剪切制备疫苗的方法及其应用
CN120418435A (zh) 一种抵抗带状疱疹的mRNA疫苗及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160428

R150 Certificate of patent or registration of utility model

Ref document number: 5932647

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250